Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension (NCT04518306), a randomized phase 3 study. The primary outcome is Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4.

2. Clinical Question

The clinical question is about short-term blood-pressure measurements, not longer-term cardiovascular outcomes. The registry describes efficacy and safety as the trial's focus and lists additional clinic and home blood-pressure measures. It does not report results for every outcome in the information summarized in the record, so conclusions should be limited to the outcomes with posted results.

3. Trial Design

This was a Phase 3, randomized, quadruple-masked, parallel-group trial of GMRx2 compared with placebo in people with hypertension. The registry lists George Medicines PTY Limited as sponsor. Enrollment was 755. The study began on 2021-06-14, reached primary completion on 2023-09-19, and is recorded as completed.

The treatment groups were Triple ¼ (GMRx2), Triple ½ (GMRx2), and placebo. The lower-dose combination contained telmisartan 10 mg, amlodipine 1.25 mg, and indapamide 0.625 mg; the other combination contained telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg. The primary endpoint analysis lists 113 participants for Triple ¼, 119 for Triple ½, and 63 for placebo. These are the group sizes associated with the posted primary endpoint results, not a complete account of participant flow.

The primary endpoint compared change in home seated mean systolic blood pressure from randomization to Week 4. The analysis description says measurements used valid systolic values greater than 60 mmHg and less than 250 mmHg, and that actual measurements and changes were summarized by timepoint and treatment group. The primary analysis population was the randomized set, with participants analyzed according to their randomized group.

The registry does not report the original sample-size assumptions or justification, detailed eligibility criteria, allocation ratio, full participant-flow accounting, or a detailed protocol for conduct of masking. It also does not report the complete statistical analysis plan in the information summarized in the record. Those omissions limit how fully the design can be reconstructed from the registry record alone.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Out of 1584 participants screened, 755 participants entered the 2-week single-blind placebo run-in period. Overall, 460 of the 755 participants who entered the run-in period were not randomized, the most common reason was failure to meet the criteria of home seated mean SBP of 130-154 mmHg in the week prior to the randomization visit. Total of 295 participants were randomized to the treatment groups at the end of run-in period.

Single-Blind Placebo Run-In Period

Double-Blind Period

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Analysis was performed on randomized set (All participants who have been randomized). Participants were analyzed in the treatment group to which they have been randomized.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Baseline characteristics were summarized on the safety population by randomized treatment groups

6. Primary Endpoint

The registry lists the primary outcome as Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4, measured over Randomization to Week 4.

The primary endpoint is the difference between treatment groups in change in home seated mean systolic blood pressure from randomization to Week 4, measured in mmHg. The registry describes valid systolic blood pressure measurements as greater than 60 mmHg and less than 250 mmHg. It also says measurements were summarized as actual values and changes from randomization to Week 4 by timepoint and group.

Change from baseline expresses how the measured outcome moved during the treatment period, while a between-group difference places that change in context against the placebo group. The posted arm-level means are changes within each group; the comparison estimates are differences between each GMRx2 group and placebo. A negative change indicates a decrease in measured systolic blood pressure, and a negative between-group estimate means the estimated change was more negative in the GMRx2 group than in placebo.

Home measurements capture blood pressure outside the clinic setting. Using a continuous outcome preserves the size of the measured change rather than reducing the result to whether someone crossed a threshold. The registry also lists clinic blood pressure and threshold-based outcomes as secondary measures. The primary endpoint does not, by itself, describe persistence beyond Week 4, cardiovascular events, or longer-term safety. Those questions are not answered by this short-term measurement.

7. Results Posted in the Registry

• Triple ¼ (GMRx2): mean -9.60 versus -2.20 on control; difference -7.40 (95% CI -10.40 to -4.40), standardized effect d = -0.73; z-test p = <0.001.
• Triple ½ (GMRx2): mean -10.40 versus -2.20 on control; difference -8.20 (95% CI -11.66 to -4.74), standardized effect d = -0.63; z-test p = <0.001.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Difference in Change in Clinic Seated Mean Mean Systolic Blood Pressure (SBP) From Randomization to Week 4

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard errors.
• Result:
  • Triple ¼ (GMRx2): mean -6.60 versus 1.30 on control; difference -7.90 (95% CI -10.87 to -4.93), standardized effect d = -0.81; z-test p = <0.001.
  • Triple ½ (GMRx2): mean -8.20 versus 1.30 on control; difference -9.50 (95% CI -12.88 to -6.12), standardized effect d = -0.77; z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Triple ¼ (GMRx2) than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Triple ½ (GMRx2) than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard errors.
• Result:
  • Triple ¼ (GMRx2): mean -3.50 versus 0.50 on control; difference -4.00 (95% CI -6.14 to -1.86), standardized effect d = -0.60; z-test p = <0.001.
  • Triple ½ (GMRx2): mean -4.30 versus 0.50 on control; difference -4.80 (95% CI -7.35 to -2.25), standardized effect d = -0.52; z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Triple ¼ (GMRx2) than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Triple ½ (GMRx2) than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and DBP <90 mmHg at Week 4

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Triple ¼ (GMRx2): 64.6% (73/113) versus 36.5% (23/63) on control; risk difference 28.1 percentage points (95% CI 13.3 to 42.9), risk ratio 1.77 (1.24–2.52); unadjusted two-proportion z-test p = <0.001.
  • Triple ½ (GMRx2): 69.7% (83/119) versus 36.5% (23/63) on control; risk difference 33.2 percentage points (95% CI 18.8 to 47.7), risk ratio 1.91 (1.35–2.70); unadjusted two-proportion z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically higher for Triple ¼ (GMRx2) than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically higher for Triple ½ (GMRx2) than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The posted secondary results cover more than one way of measuring blood pressure. They include clinic systolic and diastolic changes from randomization to Week 4 and a clinic threshold outcome at Week 4. In the results available for these measures, the direction broadly accords with the primary home systolic comparison: the GMRx2 groups show more favorable changes or threshold attainment than placebo. These secondary measures provide context across measurement setting and outcome type, but do not change what the primary endpoint measures.

Secondary results should carry less inferential weight than a prespecified primary result, especially when a study examines many outcomes. The record lists 21 outcome measures and 42 analyses, while methods for controlling the overall chance of false-positive findings across those analyses are not reported in the registry record. A p-value from one secondary comparison does not account for the full set of comparisons unless an appropriate multiplicity procedure has been applied and reported.

The results described should not be generalized to secondary endpoints whose numerical results are not included in the registry record. Nor do clinic measurements or threshold attainment establish longer-term clinical benefit. Their role is to add supporting descriptive evidence about short-term blood-pressure measurements, interpreted with attention to analysis methods, uncertainty, and the multiplicity of outcomes.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Difference in Change in Clinic Seated Mean Mean Systolic Blood Pressure (SBP) From Randomization to Week 4
• Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4
• Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and DBP <90 mmHg at Week 4
• Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4
• Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4
• Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4
• Difference in Change in Trough Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4
• Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 4

9. Statistical Interpretation

10. Statistical Methods Explained

What do the arm means represent?

The primary results report least-squares means of change in home seated mean systolic blood pressure for each randomized group. A mean is an average that summarizes the group; it does not show the spread of individual measurements. The reported standard errors describe the uncertainty of the estimated means. They are not standard deviations of participant-level blood pressure values. The outcome is continuous and measured in mmHg, so the effect can be expressed as a difference in means rather than a count of participants crossing a threshold.

General: a least-squares mean is a model-based estimate of a group mean. It can differ from a simple arithmetic average when a model accounts for features of the analysis. The registry identifies least-squares means for the primary endpoint and identifies the MIANALYZE procedure for the reported primary comparisons. The full model specification and any covariates are not reported in the registry record.

How should the comparison estimate be read?

The reported contrast is the least-squares mean change in a GMRx2 group minus the corresponding change in placebo. Thus a negative estimate indicates a more negative estimated change for the GMRx2 group. The registry reports −7.33 mmHg for Triple ¼ versus placebo and −8.23 mmHg for Triple ½ versus placebo. These are estimated differences between group means, not estimates of a response for an individual participant.

General: a treatment contrast is useful because changes can occur in both trial groups over time, including changes unrelated to the study treatment. Comparing the groups helps separate the observed difference in their average changes from the within-group changes themselves. Randomization supports this comparison by assigning participants to groups, although the registry record alone cannot establish that every possible source of bias was eliminated.

What does the p-value add?

The registry reports p < 0.001 for each primary comparison and labels both analyses as superiority. General: a p-value measures how compatible the observed data are with a specified null hypothesis under the statistical model and its assumptions. It is not the probability that the null hypothesis is true, nor does it quantify the clinical importance of the estimate. Interpretation should consider the estimate and its confidence interval as well as the p-value.

The primary reported comparisons use the MIANALYZE procedure. The registry does not describe in detail why this procedure was selected, what inputs were combined, or how missing observations were handled. Those details are not reported in the registry record. It would therefore be inappropriate to infer a particular imputation or modeling strategy from the procedure name alone.

How do the secondary analyses differ?

For the clinic systolic and diastolic continuous outcomes, the registry identifies the MMRM procedure for the reported comparisons. General: a mixed model for repeated measures can account for the correlation among repeated measurements from the same participant and estimate differences over time. The exact model structure, covariance assumptions, and covariates are not reported in the registry record. For the clinic threshold outcome, the reported analysis uses a Wald test and presents a risk difference.

A risk difference compares the proportion meeting a specified threshold in one group with the proportion in another. General: it is an absolute contrast on the probability scale, unlike a ratio measure. The posted clinic threshold analysis includes a 95% confidence interval and p-value for each comparison. The registry's methods for multiplicity adjustment across outcomes are not reported in the registry record, so these secondary p-values should be read as unadjusted evidence unless a fuller record states otherwise.

What are the recalculations?

The recalculated continuous comparisons are unadjusted estimates derived from posted arm-level means and standard errors. The pooled standard deviations used in those calculations are approximate, as indicated in the analysis details. General: a standard error measures precision of an estimated mean, while a standard deviation describes variability among individual observations. Converting between them requires assumptions and the relevant group size; an approximation from summary statistics may not match the original participant-level analysis.

For this reason, the recalculations are useful as a rough check on the scale and direction of the posted result, not as a replication of the sponsor's model. The registry-reported analyses are the primary inferential results. The original analysis plan, including model diagnostics, handling of missing data, multiplicity procedures, and any interim analysis arrangements, is not reported in the registry record.

11. Confidence Intervals and Precision

The registry reports 95% confidence intervals for both primary comparisons. For Triple ¼ versus placebo, the estimate is −7.33 mmHg and the interval runs from −10.176 to −4.486. For Triple ½ versus placebo, the estimate is −8.23 mmHg and the interval runs from −11.305 to −5.151. Both intervals lie on the negative side of zero, in keeping with the negative point estimates and the reported p-values of p < 0.001.

General: a confidence interval gives a range of values reasonably compatible with the data and the analysis model, at the stated confidence level. It communicates uncertainty in the estimated group difference, not the range of changes among individual participants. A narrower interval generally indicates more precision, while a wider interval indicates greater uncertainty. The interval does not mean there is a 95% probability that the fixed true effect lies within the particular reported bounds.

The primary intervals are those from the registry's own analyses and are preferable for interpreting the reported result. The recalculated intervals are based on unadjusted summary-statistic calculations and approximate pooled variability; they need not match the registry's model-based intervals exactly. Precision also depends on the amount and quality of data available for the analysis, assumptions of the model, and the extent of missingness. The record does not report enough detail to assess all these features independently.

The confidence intervals concern the mean difference at Week 4. They do not quantify uncertainty about longer-term effects, other populations, or clinical outcomes not measured by this endpoint. Statistical precision should therefore be kept separate from the broader scope of what the study can establish.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size figures are planning illustrations based on the observed effect, not the trial's original design assumptions. For continuous outcomes such as the primary endpoint, the figures are participants per arm. The planning assumptions listed in the registry record are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. Each planning scenario uses the stated fraction of the observed effect as the effect to detect.

The column for 80% power gives the illustrative number of participants per arm under those assumptions for an 80% chance of detecting the selected effect if it were the true effect. The 90% power column gives the corresponding illustration for a 90% chance. These are design-planning quantities, not guarantees that a future study will achieve those probabilities: the assumptions, actual effect, variability, and data completeness all matter.

Rows that plan for 100% of the observed effect use the full observed effect as the target; rows for 75% or 50% use smaller target effects. Smaller effects need more participants to detect under otherwise unchanged assumptions, which is why the planning figures increase as the target effect is reduced. A smaller target may be more conservative when planning because the observed effect in a trial can be an uncertain basis for a later study's expected effect.

For time-to-event outcomes, the registry's planning note says figures represent the total number of events, using the Schoenfeld method. That distinction does not apply to the continuous primary outcome. These calculations are not observed power; they are illustrations for future-study planning and are not a reconstruction of the trial's own sample-size justification.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = -7.400; pooled standard deviation σ = 10.146.
2. n = 2 × (1.96 + 0.842)² × 10.146² / -7.400² = 29.5, rounded up to 30 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- -7.4                      # observed difference in means
sigma <- 10.146035293843                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(4518306)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 30 (80% power), 40 (90% power)
 75% of observed effect: n per arm = 53 (80% power), 71 (90% power)
 50% of observed effect: n per arm = 119 (80% power), 159 (90% power)
power.t.test: 30.5 
Simulated power at n = 30 per arm: 0.795 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The registry's own primary analysis reports a least-squares mean difference of −7.33 mmHg for Triple ¼ versus placebo, with a 95% confidence interval from −10.176 to −4.486 and p < 0.001. For Triple ½ versus placebo, it reports −8.23 mmHg, with a 95% confidence interval from −11.305 to −5.151 and p < 0.001. Both are identified as superiority analyses using the MIANALYZE procedure.

The recalculated results are simple unadjusted comparisons based on posted group summaries, and the estimated pooled variability is approximate. They are useful for checking the broad scale and direction of the comparison, but they do not reproduce the sponsor's model or use all the participant-level information. Small differences between recalculated and registry-reported estimates or confidence limits are therefore possible.

The discrepancy indicator in the registry record is false. The sponsor's analyses are the primary inferential results to interpret, while the recalculations should be treated as supplementary checks rather than replacements. The full analysis specification that would permit an independent reproduction is not reported in the registry record.

15. Multiplicity, Missing Data and Analysis Populations

The registry lists 21 outcome measures and 42 analyses. Multiple outcomes and comparisons create a multiplicity issue: when many hypotheses are tested, the chance of at least one apparently positive result can increase even if the underlying effects are absent. General: methods such as family-wise error control or false-discovery control can address different forms of this problem, but the choice depends on the study's aims and analysis plan.

The registry record does not report whether the primary comparison was protected within a formal testing hierarchy, how secondary endpoints were ordered, or whether p-values for secondary analyses were adjusted for multiplicity. The posted secondary p-values should therefore not be interpreted as though they necessarily control the error rate across all outcomes. The primary analyses are reported as superiority comparisons, but the detailed statistical testing plan is not reported in the registry record.

The primary endpoint description identifies the randomized set and states that participants were analyzed in their assigned treatment group. This is an important analysis-population detail. However, the registry record does not report the full participant flow, the number of missing endpoint observations, the reasons for missingness, or the specific approach used to handle missing data. The MIANALYZE procedure is named for the primary comparison, but that alone does not establish the exact missing-data method or assumptions. The extent to which missingness could affect estimates cannot be evaluated from the reported information alone.

The registry also does not report whether interim analyses were conducted, whether any stopping rules were used, or the original sample-size justification. Those design and analysis details should not be inferred. A complete protocol or statistical analysis plan would be needed to assess them and to understand how outcome selection, missing data, and multiplicity were handled.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: covid-19 (3.2%), cerebrovascular accident (0.8%), arteritis (0.2%), hypertension (0.2%).

The posted adverse-event summary reports serious adverse events affecting 0 participants in Triple ¼, 3 in Triple ½, and 2 in placebo. Deaths are reported as 0 in each randomized group. The same record lists other, non-serious adverse events affecting 25 participants in Triple ¼, 32 in Triple ½, and 10 in placebo. These figures are counts of participants affected, not counts of all event episodes.

The safety summary also includes a “Not Randomized” group, with 2 participants affected by serious adverse events and 17 by other adverse events; deaths are reported as 0 for that group. This group is distinct from the randomized treatment comparisons and should not be treated as another randomized arm. The record lists COVID-19 at 3.2%, cerebrovascular accident at 0.8%, arteritis at 0.2%, and hypertension at 0.2% among the top serious adverse-event terms.

These counts describe what the registry reports and do not establish that a treatment caused an event. The registry record does not give enough detail to assess event timing, severity beyond the serious classification, exposure-adjusted rates, or whether participants had multiple events. The safety information should be read alongside the short-term follow-up and the limited group sizes, not as a complete account of longer-term risk.

17. What the Result Does, and Does Not, Mean

The result estimates differences in average change in home seated systolic blood pressure over the period from randomization to Week 4. The registry's reported estimates for both GMRx2 groups are negative relative to placebo, and both 95% confidence intervals are below zero. This is evidence of a difference in the measured short-term outcome under the stated analyses.

It does not mean that every participant's blood pressure decreased, that each participant experienced the group-average change, or that the estimated difference will be the same in another population or setting. A group mean can conceal individual variation. The results also do not establish how long a difference persists after Week 4, whether it changes the risk of cardiovascular events, or how the balance of effects changes with longer exposure.

The trial compared two combination doses with placebo; the posted primary comparisons do not establish which dose is preferable to the other. They are separate comparisons with placebo, not a direct randomized comparison between the two active groups. The registry outcome is a blood-pressure measurement and should not be confused with a patient-important clinical event.

Safety interpretation is also limited. The record reports adverse-event counts, but these alone do not determine causality or provide a complete long-term safety profile. Secondary outcomes add information about other short-term blood-pressure measures, but many outcomes were examined and the registry record does not report the multiplicity strategy. Taken together, the posted data support a carefully bounded reading of short-term measurements; they do not settle questions outside the trial's reported outcomes and timeframe.

18. Why This Trial Matters Statistically

Statistically, this trial illustrates the distinction between an arm's change over time and the treatment contrast against a comparator. The GMRx2 groups and placebo all have observed mean changes, but the primary inferential question is about the between-group difference. That contrast helps account for change that occurred in the placebo group over the same period.

It also shows why an estimate should be read together with its confidence interval. The point estimate gives the center of the estimated difference, while the interval communicates uncertainty under the analysis model. The reported primary intervals do not include zero, but statistical evidence should not be mistaken for a complete assessment of clinical importance or long-term outcomes.

The trial's multiple outcome measures also demonstrate why outcome hierarchy and multiplicity matter. A prominent primary comparison and several supporting secondary measurements do not all have the same inferential status. Without a reported multiplicity plan, secondary p-values warrant more cautious interpretation than the primary analysis.

Finally, summary-statistic recalculations can be informative while remaining distinct from a sponsor's model-based analysis. Approximate variability and unadjusted calculations can provide a scale check, but they cannot recreate all details of a participant-level analysis. Clear separation of these inferential layers is essential for responsible interpretation of registry results.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary endpoint is limited to home seated mean systolic blood pressure through Week 4. The registry record does not provide longer-term outcomes or establish whether the short-term measurement difference persists. Clinical events and other outcomes beyond those posted cannot be inferred from a blood-pressure endpoint.

The randomized group sizes associated with the primary results differ in size, and the record does not provide complete participant flow or the number of missing primary measurements. The primary analysis is described as using the randomized set and assigned groups, but missing-data handling and assumptions are not reported in the registry record. These details matter when judging how robust the estimates may be to incomplete follow-up.

The record lists many outcome measures and analyses, but does not report a multiplicity strategy. This limits interpretation of secondary significance tests. It also does not report the full model specification, covariates, diagnostic checks, interim analyses, original sample-size rationale, or detailed eligibility criteria. The posted registry information therefore cannot support a complete evaluation of every design and analysis choice.

Safety findings are reported as participant counts and selected event terms. The record does not provide enough information about exposure duration, event timing, or the relationship of events to treatment to support causal conclusions. Finally, recalculated comparisons use approximate variability from summary statistics rather than the full model. They are supplementary and do not replace the reported sponsor analyses.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension — NCT04518306.
• Registry record last updated 2025-06-03; status last verified 2025-05.
• Results first posted 2025-06-03.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

This completed Phase 3 trial randomized participants with hypertension to Triple ¼ GMRx2, Triple ½ GMRx2, or placebo in a quadruple-masked, parallel-group design. Enrollment was 755. The primary endpoint was change in home seated mean systolic blood pressure from randomization to Week 4.

The registry reports a least-squares mean difference versus placebo of −7.33 mmHg for Triple ¼ and −8.23 mmHg for Triple ½. Each reported 95% confidence interval lies below zero, and each p-value is p < 0.001. These are short-term estimates for the measured blood-pressure outcome. Additional clinic blood-pressure outcomes and adverse-event counts are posted, but multiplicity, missing-data methods, full analysis specifications, and original sample-size assumptions are not reported in the registry record.